FibroGen is discovering and developing first-in-class therapeutics for anemia, fibrotic disease and cancer. Pamrevlumab is a human monoclonal antibody against CTGF entering Phase 3 clinical development as a neoadjuvant therapy for locally advanced unresectable pancreatic cancer (LAPC). In a Phase 2 clinical study, pamrevlumab was well-tolerated in combination with gemcitabine and nab-paclitaxel. Further, a higher proportion of pamrevlumab-treated patients were eligible for surgical exploration and achieved resection, as compared to patients treated with chemotherapy alone.